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1. Introduction
   Influenza virus infection remains a major cause of 
morbidity and mortality during winter months almost 
every year. Influenza viruses can cause global epidemic 
diseases, known as pandemics, during which rates of 
illness and death from influenza-related complications 
can increase dramatically[1,2]. High infection rates, short 
incubation periods, and rapid progression of the disease 
through the population are characteristic of influenza. 
Its hallmark is its epidemicity, and its impact on public 
health is dramatic. The final H1N1 statistics from Centers 
for Disease Control estimate that, between April 2009 and 
April 10, 2010, there were between 43 million and 89 million 
cases of 2009 H1N1 of which 195 000 and 403 000 in 2009 H1N1 
were related hospitalizations[3]. The control of viral diseases 
has been a subject of intense scientific endeavor. There is 
an increasing need to find new molecules or compounds 
with antiviral activity for the treatment of viral infections 
because in recent years it has reported an increase of 
mutations to antiviral against Flu-A.
   Influenza Type A (Flu-A) and influenza Type B (Flu-B) 
are two types of influenza viruses. Flu-A virus is further 
categorized into subtypes based on two surface antigens: 
hemagglutinin and neuraminidase. Vaccination remains 
the primary method for prevention of influenza, but 
vaccine strains must be continually updated and their 
protective efficacy is limited in people over 65 years of age 
who paradoxically are the group most severely affected 
by influenza[4]. An alternative to failed vaccination is the 
administration of antiviral drugs. Two influenza inhibitors 
designed based on the structure of viral neuraminidase, 
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zanamivir® and oseltamivir carboxylate®, have been 
approved for treatment and prophylaxis of influenza 
infection[5,6]. Amantadine® and rimantadine® are other 
chemically related agents with antiviral activity against 
Flu-A virus but not against Flu-B virus[7]. Amantadine has 
been used in the treatment and prevention of Flu-A virus 
infection for over three decades. Its use is associated with 
severity of symptoms and duration of illness[8]. Amantadine 
takes effects by blocking the ion channel activity of the 
matrix protein and inhibiting replication of Flu-A viruses. 
However, these viruses can rapidly become drug-resistant 
during treatment[9].
   The aim of the present study is to evaluate in vitro the 
antiviral activity of Lepidium meyenii (L. meyenii) (maca) 
against respiratory viruses. L. meyenii (Walpers), also 
reported as Lepidium peruvianum (Chacón) and commonly 
known as maca, is a perennial herbaceous plant that grows 
in the Peruvian Central Andes (3 700-4 500 m of altitude). 
Maca has been consumed since the times of the pre-
Incas and Incas. This tuber has an excellent nutritional 
value because of its high content in carbohydrates, 
proteins, vitamins and minerals[10]. Thus, maca is a 
powerful energizer, particularly indicated in cases of 
undernourishment or stress because it improves physical 
and mental energy[11].  Recently, diverse secondary 
metabolites of maca have been identified[12-14], and possible 
therapeutic applications to cancer[15], immune[16,17], and 
reproductive[18], disorders have been suggested. Also, for 
the first time ever, this work describes the antiviral activity 
of the methanol extract of L. meyenii against Flu-A and 
Flu-B viruses. Our results clearly show that this extract has 
a potent antiviral activity and would complement the use 
of maca as traditional medicine to treat respiratory virus 
infection.
2. Materials and methods
2.1. Plant material and extracts
   L. meyenii (maca) was obtained in the Pampas Valley 
(Tayacaja, Huancavelica), in the Peruvian Andes. This 
plant is sold by neighboring farmers without the need of a 
marketing permit as maca is not considered a threatened or 
protected plant species. Maca root powder was macerated 
in pure methanol (1:2, v/v) for 10 d. The macerated mixture 
was filtered, and the eluted methanol was dried at 40 °C for 
complete evaporation of methanol[15]. Finally, dilutions were 
performed to evaluate antiviral activity. The same process 
was used to prepare an aqueous extract.
2.2. Cell lines 
   Madin-Darby canine kidney (MDCK) cells were obtained 
from American Type Culture Collection, USA. The cells 
were grown in minimum essential medium with Earle’s 
salts (Gibco BRL, Grand Island, NY) supplemented with 
10% foetal bovine serum, 25 μg/L gentamicin and 200 
mmol/L L-glutamine (growth medium). Infected cells 
were maintained in minimum essential medium with 1% 
foetal bovine serum, 25 μg/L gentamicin and 200 mmol/L 
L-glutamine (maintenance medium). All cells were cultured 
at 37 °C in a humidified atmosphere with 5% CO2-95% air.
2.3. Viruses
   Human influenza Type A virus (Flu-A or H1N1 strain 
A/New Caledonia/20/99) and Human influenza-B virus 
(Flu-B or strain Shanghai/361/2002) were obtained from the 
respiratory virus laboratory (Hospital Clínic of Barcelona, 
Barcelona, Spain) and used for in vitro assays as follows: 
the viruses were adapted and passaged more than twice in 
respective host cells (MDCK cells). When a cytopathic effect 
(CPE) characteristic of both viral infections was observed, 
the infected cultures were centrifuged at 3 000 r/min for 10 
min and supernatants stored at -80 °C until use. For virus 
titration, cells grown in 96-well plates were incubated at 37 
°C for 2 h with decimal dilutions of virus suspensions. After 
absorption, the inoculum was removed and maintenance 
culture medium was added. Titres were calculated as 
50% cell culture infectious doses (TCID50)/mL to estimate 
endpoints by the Reed-Muench method[19]. All plates were 
incubated at 37 °C and observed daily to determine the CPE. 
Endpoints were estimated on the 6th day.
2.4. Cytotoxicity assay
   Cytotoxicity of maca extract was assessed using an assay 
based on the color change subsequent to the reduction 
of 3-[4,5-dimethylthiazol-2-y1]-2,-diphenyltetrazolium 
bromide (MTT) by mitochondrial enzymes[20-22]. The assays 
were performed using 1伊104 cell/well in 200 μL of medium 
which were cultured in 96-well plates and incubated at 
37 °C in a humidified atmosphere with 5% CO2- 95% air. 
When cell cultures were confluent, the culture medium was 
removed from the wells, which were replenished with 0.2 
mL of the maintenance medium containing maca extract 
prepared by dilution. Maca concentrations had a range from 
0 to 1 000 μg/mL. Each dose was assayed in quadruplicate. 
The wells with 0.2 mL maintenance medium but without 
virus samples were used as cell controls. All cultures were 
incubated at 37 °C for 6 d. Cell morphology was inspected 
daily for alterations. Cytotoxic concentration 50% (CC50) is 
defined as the concentration of compound that reduces 
the viability of mock-infected cells by 50%. This index is 
commonly estimated by MTT assay. In our study, 20 μL of 
MTT stock solution (3 mg/mL in phosphate buffered saline) 
was added to each well. After 3 h of incubation under 
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culture conditions, the medium was carefully removed 
and formazan crystals were solubilized by adding 200 μL 
dimethyl sulfoxide. Finally, cell viability was expressed 
as the percentage of the absorbance value determined for 
the control cultures. Absorbance (A570 nm) was measured 
in an ELISA reader. CC50 was then determined using Pharm/
PCS software[23]. To confirm MTT results, the monolayers 
were also observed microscopically to estimate the CPE i.e. 
rounding and other marked morphological changes with 
respect to control cells[20]. 
2.5. Antiviral activity assay
   Antiviral activity of compounds against Flu-A and 
Flu-B viruses was assayed using a test for determining 
the inhibition of CPE on cell culture[24-26]. MDCK cells were 
seeded at 104 cells/well in 96-well plates and allowed to 
attach overnight. The next day they were washed with 
phosphate buffered saline and inoculated with virus 
suspension at a multiplicity of infection of 0.01 except for 
the control well. Amantadine was used as positive control. 
After 120 min of incubation at 37 °C, 100 μL/well of culture 
medium containing different concentrations of maca extract 
was added to confluent monolayers of cells. All cultures 
were carried out in quadruplicate and incubated at 37 °C 
in 5% CO2 atmosphere for 6 d until control wells showed 
70-100% CPE. All wells were then observed under a light 
microscope to determine CPE. Minimal inhibitory drug 
concentration that reduced CPE by 50% (IC50) was calculated 
by MTT method[20,21].
2.6. Amplification of influenza virus by RT-PCR
   A multiplex RT-PCR assay was performed to amplify highly 
conserved genes of Flu-A and Flu-B virus nucleoprotein[27]. 
Flu-A viruses were detected using primers: sense 5’-GAA 
CTC RTY CYW WAT SWC AAW GRR GAA AT-3’ and antisense 5’-
ATK GCG CWY RAY AMW CTY ARR TCT TCA WAI GC-3’. Flu-B 
viruses were detected using primers: sense 5’- ACA GAG ATA 
AAG AAG AGC GTC TAC AA-3’ and antisense 5’- ATK GCG CWY 
RAY AMW CTY ARR TCT TCA WAI GC-3’.
   Nucleic acids of both types of viruses propagated in cell 
cultures were extracted from 200 μL of the sample by the 
guanidinium thiocyanate method[28]. After processing, the 
dry pellet was resuspended in 15 μL of sterile RNase-free 
water.
   RT-PCR amplification reaction was performed in a single 
step using the RT-PCR system kit (Promega), which consisted 
in a PCR mixture containing 2 mmol/L MgSO4, 300 μmol/
L of each deoxyadenosine triphosphate, deoxyguanosine 
t r i phospha te ,  deoxycy t id ine  t r i phospha te  and 
deoxythymidine triphosphate, 20 pmol of specific primers for 
Flu-A or Flu-B viruses, 10 μL of 5伊 reaction buffer, 5 IU of 
cloned avian myeloblastosis virus reverse transcriptase, and 
5 IU of Tfl DNA polymerase. An aliquot 5 μL of RNA extract 
was added to a reaction final volume of 50 μL. Amplification 
reactions were carried out in a PTC-200 (Peltier Thermal 
Cycler, MJ Research, Watertown, MA). Samples were subject 
to an initial cycle of 48 °C for 45 min, and then 94 °C for 3 
min. The cycles conditions of the PCR were 45 cycles: 94 °C 
for 30 seconds; 55 °C for 1.5 min; 72 °C for 1 min, and a final 
incubation of 72 °C for 10 min. PCR products were analyzed 
by electrophoresis on 2% gel agarose (FMC, Rockland, ME) 
containing 3 μg/mL of ethidium bromide in 1伊 Tris-borate 
buffer. The amplicon sizes were 721 and 991 bp for Flu-A 
and Flu-B, respectively.
3. Results
3.1. Toxicity of maca extract
   The toxicity of the aqueous and methanol extracts of maca 
was determined using MDCK cells for virus propagation. 
MDCK cells were incubated with increasing amounts (from 
0 to 1 000 μg/mL) of maca extract and cell viability was 
determined by MTT method. Relative viability of MDCK 
cells was calculated by comparison with untreated cultures 
(control, 0 μg/mL). Results indicate that the aqueous extract 
did not produce adverse effects on MDCK cells (Figure 1). 
However, the methanol extract showed CC50 of 850 μg/mL, 
but no toxic effect was observed in concentrations below 
200 μg/mL. These values were confirmed by microscopic 
observation of CPE. Thus, the methanol extract can contain 
the active compounds of maca to produce biological effects.
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Figure 1. Cytotoxic effect of aqueous and methanol extracts of maca on 
MDCK cells. 
Valures are mean依SD of three independent experiments.
3.2. Antiviral activity of maca extract
   The ability of maca extract to inhibit influenza virus 
replication in MDCK cells was examined. Cell viability often 
decreases during viral propagation. Thus, an increase in 
Juana del Valle Mendoza et al./Asian Pac J Trop Med 2014; 7(Suppl 1): S415-S420S418
cell viability means inhibition of viral propagation (antiviral 
effect). The methanol extract of maca exhibited a potent 
activity against Flu-A (Figure 2) and Flu-B (Figure 3) 
viruses. Concentrations in the range of 10-80 μg/mL were 
effective in producing an antiviral effect by re-establishing 
normal growth of MDCK cells. The half inhibitory 
concentration (IC50) for Flu-A virus was 5.4 μg/mL (Table 1 
and Figure 2a), a value found after determining cell viability 
of MDCK cells. Our results show a good correlation between 
IC50 and the RT-PCR product of the viral nucleoprotein 
(Figure 2b). Commercial amantadine was used as positive 
control and had a clear inhibitory effect on Flu-A virus 
(Figure 2). It reduced viral load (Figure 2b), increasing cell 
viability of infected cells (Figure 2a). Flu-B virus replication 
was inhibited with an IC50 of 7.69 μg/mL (Table 1 and Figure 
3a). Viral inhibition was reflected by the decrease of viral 
nucleoprotein or viral load in MDCK cells (Figure 3b).
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Figure 2. Antiviral activity of maca methanol extract against Flu-A. 
a: MDCK cells infected with Flu-A, then treated with methanol extract of 
maca. CTRL: treatment with amantadine (1 μg/mL); *: P<0.05 compared with 
dose 0 using Tukey test; b: RT-PCR for viral nucleoprotein gene. C: cells 
treated with amantadine; M: DNA marker.
   The selectivity index (SI), a therapeutic indicator, was 
calculated as the ratio between CC50 and IC50. SI values 
obtained for Flu-A and Flu-B are shown in Table 1. The 
SI determines the magnitude of the antiviral effect of the 
methanol extract of maca. Thus, this extract contains 
compounds with anti-influenza properties of therapeutic 
interest, especially against Flu-A.
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Figure 3. Antiviral activity of maca extract against Flu-B. 
a: MDCK cells infected with Flu-B, then treated with methanol extract of 
maca; *: P<0.05 compared with dose 0 by using Tukey test; b: RT-PCR for 
nucleoprotein gene of Flu-B; M: DNA marker.
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4. Discussion
   Traditional herbal medicine has been used for the 
treatment of human infectious diseases in many countries 
for centuries. Combining with ethnopharmacology, it 
could be an alternative approach to the discovery of 
antiviral agents. The results of our study show that the 
methanol extract of maca has antiviral effects on influenza 
similar to those of amantadine antiviral.
Table 1
Antiviral activity of methanol extract of maca against Flu-A (H1N1) and Flu-B on MDCK cells.
Compounds Flu-A (H1N1) Flu-B Reference
IC50 (μg/mL)
a
CC50 (μg/mL)
b
SI
c
IC50 (μg/mL)
a
CC50 (μg/mL)
b
SI
c
Maca extract   5.4 850.0 157.4 7.69 850 110.5 This study
7-O-galloyltricetiflavan 15.7 110.0 7.0 - - - [29]
7,4-Di-O- galloyltricetiflavan 30.0   60.0 2.0 - - - [29]
Quercetin-3-O-β-D-glucopyranosyl 24.5  392.5    16.0 - - - [29]
Ribavirind 62.5        >125.0   >2.0 - - - [30]
a: IC50 is the concentration of compound required to inhibit virus-induced CPE by 50%; b: CC50 is the concentration of 50% cytotoxic effect; c: 
SI: CC50/IC50; d: Positive control drug.
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   Recently, two new antiviral flavan derivatives were 
isolated from leaves of Pithecellobium clypearia 
(Fabaceae). These compounds have antiviral activity 
against respiratory syncytial virus, Flu-A (H1N1), 
coxsackie B3 (Cox B3), and herpes simplex virus Type 
1[29]. Other flavonoids obtained from Avicennia marina 
(Avicenniaceae) possess antiviral activity against 
HIV and herpes virus (HSV-1, HSV-2) inhibiting viral 
multiplication[30,31]. New flavonoids isolated from the 
antiviral fraction of Wikstroemia indica against respiratory 
syncytial virus[32]. Thus, it has been demonstrated that 
polyphenolic compounds may be effective against 
viral infections. In addition to these compounds, other 
constituents in plant extracts may contribute to antiviral 
activity[33], for example tannins, a group of secondary 
metabolites ubiquitous in plants[34]. 
   Very few studies deal with antiviral compounds against 
virus. Tannins from persimmon (Diospyros kaki) extract 
have been reported to inhibit to 12 different viruses 
including both enveloped viruses (influenza virus H3N2, 
H5N3, herpes simplex virus-1, vesicular stomatitis virus, 
Sendai virus and Newcastle disease virus) and non-
enveloped viruses (poliovirus, coxsachievirus, adenovirus, 
rotavirus, feline calicivirus and mouse norovirus)[35]. Our 
study clearly demonstrates that the methanol extract 
of maca can inhibit Flu-A and Flu-B virus growth and 
has a high therapeutic index compared to other antiviral 
compounds.
   Now it is known that maca contains secondary 
metabolites with several medicinal properties, such as 
compounds for ovarian stimulation in rats to increase 
the number of ovarian follicles[15], and spermatogenesis 
stimulation in rats[18], and compounds with anti-oxidative 
properties[15,36].  These effects could be due to the 
presence of biologically active isothiocyanates (e.g. benzyl 
isothiocyanate and p-methoxy benzyl isothiocyanate)[29]. 
Other phytochemical components of maca with potential 
medicinal effects are essential fatty acids (e.g. linoleic 
and oleic), flavonoids and saponins[31], alkaloids[14], 
benzoyl derivatives[10], and glucosinolates[14].
   Here we report that the methanol extract of L. meyenii 
(maca) has an inhibitory effect on Flu-A and Flu-B virus 
replication. Standard cell-based assays were conducted to 
determine this antiviral activity by quantitative analysis 
of flu virus replication, monitoring of CPE and detection 
of the conserved nucleoprotein sequence in flu viruses by 
RT-PCR, a very sensitive and rapid detection method for 
screening potential antiviral agents. Our results suggest 
that the antiviral activity of maca extract have several 
possible targets in flu viruses. The antiviral compounds 
of maca can interfere with virus attachment or prevent 
virus-cell fusion; therefore, the amount of envelop protein 
on the surface of infected cells is a key endpoint for 
infection control. Maca extract also decreases viral load 
via post-entry of Flu infection.
   In conclusion, since L. meyenii (maca) extract shows 
in vitro inhibitory properties against Flu-A and Flu-B 
viruses, it may represent a novel therapeutic treatment 
with antiviral activity for influenza infection. Finally, this 
study opens a new avenue for scientific inquiry on these 
effective compounds against human influenza.
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